cholera vaccines

Summary

Summary: Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist.

Top Publications

  1. ncbi Cholera
    David A Sack
    International Centre for Diarrhoeal Disease Research, Bangladesh, Centre for Health and Population Research, Dhaka, Bangladesh
    Lancet 363:223-33. 2004
  2. ncbi Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial
    Dipika Sur
    National Institute of Cholera and Enteric Diseases, Kolkata, India
    Lancet 374:1694-702. 2009
  3. pmc Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial
    Dipika Sur
    National Institute of Cholera and Enteric Diseases, Kolkata, India
    PLoS Negl Trop Dis 5:e1289. 2011
  4. ncbi Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis
    Mohammad Ali
    International Vaccine Institute, Seoul, Korea
    Lancet 366:44-9. 2005
  5. ncbi Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age
    Amit Saha
    International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh
    Vaccine 29:8285-92. 2011
  6. pmc Considerations for oral cholera vaccine use during outbreak after earthquake in Haiti, 2010-2011
    Kashmira A Date
    Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Emerg Infect Dis 17:2105-12. 2011
  7. pmc Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice
    Stefan Schild
    Department of Molecular Biology and Microbiology, Howard Hughes Medical Institute, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Infect Immun 76:4554-63. 2008
  8. pmc Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy
    Ramadhan Hashim
    International Vaccine Institute, Seoul, Korea
    PLoS Negl Trop Dis 6:e1743. 2012
  9. pmc Use of oral cholera vaccine in Haiti: a rural demonstration project
    Louise C Ivers
    Division of Global Health Equity, Brigham and Women s Hospital, Boston, Massachusetts Partners In Health, Boston, Massachusetts Zanmi Lasante, St Marc, Haiti Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts Ministry of Health and Population, Port au Prince, Haiti
    Am J Trop Med Hyg 89:617-24. 2013
  10. pmc Controlling endemic cholera with oral vaccines
    Ira M Longini
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS Med 4:e336. 2007

Detail Information

Publications174 found, 100 shown here

  1. ncbi Cholera
    David A Sack
    International Centre for Diarrhoeal Disease Research, Bangladesh, Centre for Health and Population Research, Dhaka, Bangladesh
    Lancet 363:223-33. 2004
    ..Appropriate case management has reduced deaths from diarrhoeal disease by an estimated 3 million per year compared with 20 years ago. Vaccination was thought to have no role for cholera, but new oral vaccines are showing great promise...
  2. ncbi Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial
    Dipika Sur
    National Institute of Cholera and Enteric Diseases, Kolkata, India
    Lancet 374:1694-702. 2009
    Oral cholera vaccines consisting of killed whole cells have been available for many years, but they have not been used extensively in populations with endemic disease...
  3. pmc Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial
    Dipika Sur
    National Institute of Cholera and Enteric Diseases, Kolkata, India
    PLoS Negl Trop Dis 5:e1289. 2011
    Killed oral cholera vaccines (OCVs) have been licensed for use in developing countries, but protection conferred by licensed OCVs beyond two years of follow-up has not been demonstrated in randomized, clinical trials.
  4. ncbi Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis
    Mohammad Ali
    International Vaccine Institute, Seoul, Korea
    Lancet 366:44-9. 2005
    Decisions about the use of killed oral cholera vaccines, which confer moderate levels of direct protection to vaccinees, can depend on whether the vaccines also provide indirect (herd) protection when high levels of vaccine coverage are ..
  5. ncbi Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age
    Amit Saha
    International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh
    Vaccine 29:8285-92. 2011
    ..Safety and immunogenicity study of an oral, killed, bivalent whole-cell, cholera vaccine, Shanchol was carried out in Bangladeshi participants. This study was conducted prior to initiating a feasibility study in Bangladesh...
  6. pmc Considerations for oral cholera vaccine use during outbreak after earthquake in Haiti, 2010-2011
    Kashmira A Date
    Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Emerg Infect Dis 17:2105-12. 2011
    Oral cholera vaccines (OCVs) have been recommended in cholera-endemic settings and preemptively during outbreaks and complex emergencies. However, experience and guidelines for reactive use after an outbreak has started are limited...
  7. pmc Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice
    Stefan Schild
    Department of Molecular Biology and Microbiology, Howard Hughes Medical Institute, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Infect Immun 76:4554-63. 2008
    ..These findings may contribute to the development of "nonliving," OMV-based vaccines against V. cholerae and other enteric pathogens, using the oral or intranasal route of immunization...
  8. pmc Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy
    Ramadhan Hashim
    International Vaccine Institute, Seoul, Korea
    PLoS Negl Trop Dis 6:e1743. 2012
    Mass vaccinations are a main strategy in the deployment of oral cholera vaccines. Campaigns avoid giving vaccine to pregnant women because of the absence of safety data of the killed whole-cell oral cholera (rBS-WC) vaccine...
  9. pmc Use of oral cholera vaccine in Haiti: a rural demonstration project
    Louise C Ivers
    Division of Global Health Equity, Brigham and Women s Hospital, Boston, Massachusetts Partners In Health, Boston, Massachusetts Zanmi Lasante, St Marc, Haiti Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts Ministry of Health and Population, Port au Prince, Haiti
    Am J Trop Med Hyg 89:617-24. 2013
    ..Despite logistics and cold chain challenges, 45,417 persons were successfully vaccinated with OCV in the region, and 90.8% of these persons completed their second dose...
  10. pmc Controlling endemic cholera with oral vaccines
    Ira M Longini
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS Med 4:e336. 2007
    ..Internationally licensed, killed whole-cell based oral cholera vaccines (OCVs) have been available for over a decade, but have not been used for the control of cholera...
  11. ncbi Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR
    P J Cooper
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 0425, USA
    J Infect Dis 182:1199-206. 2000
    ..lumbricoides infections impair the immune response to oral cholera vaccine, particularly in subjects of non-O blood groups...
  12. pmc Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera
    Mohammad Murshid Alam
    Immunology Unit, Laboratory Sciences Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Mohakali, Dhaka 1212, Bangladesh
    Clin Vaccine Immunol 18:844-50. 2011
    ..These findings may explain in part the relatively short-term protection afforded by oral cholera vaccination compared to natural disease...
  13. ncbi Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development
    J J Mekalanos
    Nature 306:551-7. 1983
    ..Incorporation of defined in vitro-generated ctx deletion mutations into Vibrio cholerae by in vivo genetic recombination produced strains which have practical value in cholera vaccine development...
  14. ncbi Social and cultural determinants of anticipated acceptance of an oral cholera vaccine prior to a mass vaccination campaign in Zanzibar
    Christian Schaetti
    Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Hum Vaccin 7:1299-308. 2011
    ....
  15. ncbi Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge
    Juthika Kundu
    Division of Microbiology, Central Drug Research Institute, Lucknow, India
    FEMS Immunol Med Microbiol 56:179-84. 2009
    ..Thus, mucosal codelivery of pertinent cholera toxoids provides enhanced protection against experimental cholera...
  16. pmc Community participation in two vaccination trials in slums of Kolkata, India: a multi-level analysis
    Mohammad Ali
    International Vaccine Institute, Seoul, Korea
    J Health Popul Nutr 28:450-7. 2010
    ..The results illustrated that participation in the trial was mostly influenced by various individual and community-level factors, which need to be addressed for a successful vaccination campaign...
  17. pmc Vibrio cholerae: lessons for mucosal vaccine design
    Anne L Bishop
    Department of Molecular Biology and Microbiology, Tufts University School of Medicine and Howard Hughes Medical Institute, Boston, MA 02111, USA
    Expert Rev Vaccines 10:79-94. 2011
    ..will continue to confound our ability to eradicate cholera through improvements to infrastructure, and thus cholera vaccines are needed...
  18. pmc Vaccination strategies for epidemic cholera in Haiti with implications for the developing world
    Dennis L Chao
    Center for Statistics and Quantitative Infectious Diseases, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Proc Natl Acad Sci U S A 108:7081-5. 2011
    ..Interventions have included treatment of cases and improved sanitation. Use of cholera vaccines would likely have further reduced morbidity and mortality, but such vaccines are in short supply and little ..
  19. ncbi Effectiveness of mass oral cholera vaccination in Beira, Mozambique
    Marcelino E S Lucas
    Ministry of Health, Maputo, Mozambique
    N Engl J Med 352:757-67. 2005
    New-generation, orally administered cholera vaccines offer the promise of improved control of cholera in sub-Saharan Africa...
  20. ncbi Cholera: a new homeland in Africa?
    Nicholas H Gaffga
    Division of Foodborne, Mycotic, and Enteric Diseases, National Center for Zoonotic, Vectorborne, and Enteric Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Am J Trop Med Hyg 77:705-13. 2007
    ..The persistence or control of cholera in Africa will be a key indicator of global efforts to reach the Millennium Development Goals and of recent commitments by leaders of the G-8 countries to increase development aid to the region...
  21. pmc The case for reactive mass oral cholera vaccinations
    Rita Reyburn
    International Vaccine Institute IVI, Seoul, Korea
    PLoS Negl Trop Dis 5:e952. 2011
    ..for the long term control of cholera, there is controversy about the role of newer approaches such as oral cholera vaccines (OCVs)...
  22. ncbi Oral vaccines against cholera
    Sunheang Shin
    International Vaccine Institute, Seoul, South Korea
    Clin Infect Dis 52:1343-9. 2011
    ..The advent of safe and effective, new-generation oral vaccines against cholera has created renewed interest in the use of vaccines as a tool to control cholera...
  23. pmc Sensitive microplate assay for detection of bactericidal antibodies to Vibrio cholerae O139
    Stephen R Attridge
    Department of Molecular Biosciences, University of Adelaide, Adelaide, South Australia 5005, Australia
    Clin Diagn Lab Immunol 9:383-7. 2002
    ..Although infection generated stronger responses than vaccination, the proportion of responders was similar among individuals with low background titers...
  24. pmc Urban cholera transmission hotspots and their implications for reactive vaccination: evidence from Bissau city, Guinea bissau
    Andrew S Azman
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America
    PLoS Negl Trop Dis 6:e1901. 2012
    Use of cholera vaccines in response to epidemics (reactive vaccination) may provide an effective supplement to traditional control measures...
  25. ncbi Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India
    Mohammad Ali
    International Vaccine Institute, Seoul, Republic of Korea
    Clin Infect Dis 56:1123-31. 2013
    ..We evaluated the herd protection conferred by an oral cholera vaccine using 2 approaches: cluster design and geographic information system (GIS) design...
  26. pmc Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera
    Stefan Schild
    Howard Hughes Medical Institute and Department of Molecular Biology and Microbiology, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA
    Infect Immun 77:472-84. 2009
    ..The detection of an immune response against this heterologously expressed protein is a promising step toward the potential use of OMVs as antigen delivery vehicles in vaccine design...
  27. ncbi Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study
    Ahmed M Khatib
    Ministry of Health, Zanzibar, Tanzania
    Lancet Infect Dis 12:837-44. 2012
    ..We assessed the effectiveness of oral cholera vaccination in high-risk populations in the archipelago to estimate the indirect (herd) protection conferred by the vaccine and direct vaccine effectiveness...
  28. pmc Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid
    A Boutonnier
    , , Institut Pasteur, 75724 Paris Cedex 15, France
    Infect Immun 69:3488-93. 2001
    ..They were also protective in the neonatal mouse model of cholera infection. The conjugation of the O139 pmLPS, therefore, enhanced its immunogenicity and conferred T-dependent properties to this polysaccharide...
  29. pmc Social and cultural determinants of oral cholera vaccine uptake in Zanzibar
    Christian Schaetti
    Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Hum Vaccin Immunother 8:1223-9. 2012
    ..Findings recommend particular efforts to increase cholera immunization coverage among young adults, in peri-urban areas and for men...
  30. pmc Mass vaccination with a two-dose oral cholera vaccine in a refugee camp
    D Legros
    Epicentre, Kampala, Uganda
    Bull World Health Organ 77:837-42. 1999
    In refugee settings, the use of cholera vaccines is controversial since a mass vaccination campaign might disrupt other priority interventions...
  31. ncbi When should cholera vaccine be used in cholera-endemic areas?
    David A Sack
    J Health Popul Nutr 21:299-303. 2003
  32. pmc Use of oral cholera vaccines in an outbreak in Vietnam: a case control study
    Dang Duc Anh
    National Institute of Hygiene and Epidemiology NIHE, Hanoi, Vietnam
    PLoS Negl Trop Dis 5:e1006. 2011
    Killed oral cholera vaccines (OCVs) are available but not used routinely for cholera control except in Vietnam, which produces its own vaccine...
  33. ncbi Private demand for cholera vaccines in Hue, Vietnam
    Dohyeong Kim
    University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Value Health 11:119-28. 2008
    This study aims to measure the private demand for oral cholera vaccines in Hue, Vietnam, an area of relatively low endemicity of cholera, using the contingent valuation method.
  34. pmc Oral cholera vaccine use in Zanzibar: socioeconomic and behavioural features affecting demand and acceptance
    Christian Schaetti
    Department of Public Health and Epidemiology, Swiss Tropical Institute, PO Box, Socinstrasse 57, 4002 Basel, Switzerland
    BMC Public Health 9:99. 2009
    ....
  35. pmc A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India
    Dilip Mahalanabis
    Society for Applied Studies, Kolkata, India
    PLoS ONE 3:e2323. 2008
    ..This vaccine was reformulated to meet WHO requirements. We assessed the safety and immunogenicity of the reformulated bivalent (Vibrio cholerae 01 and 0139) killed whole cell oral vaccine in a cholera endemic area in Kolkata, India...
  36. ncbi Relationship between neighbourhood-level killed oral cholera vaccine coverage and protective efficacy: evidence for herd immunity
    Michael Emch
    Department of Geography, Saunders Hall, Campus Box 3220, University of North Carolina Chapel Hill, 27599 3220, USA
    Int J Epidemiol 35:1044-50. 2006
    ....
  37. ncbi Coverage and costs of mass immunization of an oral cholera vaccine in Vietnam
    Dinh Thiem Vu
    National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
    J Health Popul Nutr 21:304-8. 2003
    ..89. Mass immunization with this locally-produced oral, killed cholera vaccine was found to be feasible and affordable with attainment of high vaccination coverage...
  38. ncbi Private demand for cholera vaccines in Beira, Mozambique
    Marcelino E S Lucas
    Ministry of Science and Technology, Maputo, Mozambique
    Vaccine 25:2599-609. 2007
    ..We estimate average household willingness to pay (WTP) for cholera vaccines in Beira to be 2005 US$ 8.45...
  39. ncbi Vaccination with Dukoral against travelers' diarrhea (ETEC) and cholera
    Tomas Jelinek
    Berlin Center for Travel and Tropical Medicine, Berlin, Germany
    Expert Rev Vaccines 7:561-7. 2008
    ..Vaccination against cholera and ETEC should be recommended for at-risk travelers, in particular those with high exposure at their travel destination or high personal risks through fluid loss...
  40. pmc Human infection with Ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin B subunit following vaccination with the live oral cholera vaccine CVD 103-HgR
    P J Cooper
    Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Infect Immun 69:1574-80. 2001
    ..The potential modulation of the immune response to oral vaccines by geohelminth parasites has important implications for the design of vaccination campaigns in geohelminth-endemic areas...
  41. ncbi Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam
    Vu Dinh Thiem
    National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
    Vaccine 24:4297-303. 2006
    ..The overall vaccine effectiveness 3-5 years after vaccination was 50% (9-63%). This low-cost, easily administered vaccine should be considered as a tool for the control of cholera...
  42. ncbi Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults
    Dang Duc Anh
    National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
    Vaccine 25:1149-55. 2007
    ..We found that this reformulated oral killed whole-cell cholera vaccine was safe, well tolerated and highly immunogenic...
  43. ncbi Efficacy calculation in randomized trials: global or local measures?
    Michael Emch
    Department of Geography, Saunders Hall, University of North Carolina, Chapel Hill, NC 27599 3220 USA
    Health Place 13:238-48. 2007
    ..Local efficacy measures can help public health practitioners make better decisions about when and where to vaccinate populations. The concepts offered in this study are pertinent for any health intervention trial, not just vaccines...
  44. ncbi An overview of cholera vaccines and their public health implications
    Sachin N Desai
    International Vaccine Institute, Seoul, South Korea
    Curr Opin Pediatr 24:85-91. 2012
    ....
  45. pmc Knowledge of, attitudes toward, and preventive practices relating to cholera and oral cholera vaccine among urban high-risk groups: findings of a cross-sectional study in Dhaka, Bangladesh
    Tasnuva Wahed
    Centre for Vaccine Sciences, ICDDR, B, Dhaka, Bangladesh
    BMC Public Health 13:242. 2013
    ..b>Cholera vaccines not only provide health benefits to susceptible populations but also have effects on the earning capabilities ..
  46. ncbi Live attenuated oral cholera vaccines
    Edward T Ryan
    Massachusetts General Hospital Tropical and Geographic Medicine Center, Division of Infectious Diseases, Jackson 504 55 Fruit Street, Boston, MA 02114, USA
    Expert Rev Vaccines 5:483-94. 2006
    ..cholerae infection. The concern remains that live oral cholera vaccines may be less effective among partially immune individuals in cholera endemic areas as pre-existing antibodies ..
  47. pmc Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans
    M Jertborn
    Department of Medical Microbiology and Immunology, Department of Gastroenterology, Sahlgrenska University Hospital, Goteborg, Sweden
    Infect Immun 69:4125-8. 2001
    ..Antitoxin antibody responses in rectal secretions and serum were also found...
  48. ncbi Sample size determination for phase II studies of new vaccines
    Malla R Rao
    National Institute of Child Health and Human Development, Bethesda, MD 20892, USA
    Vaccine 20:3364-9. 2002
    ..We also consider a setting in which the desire is to show that the difference between immune response rates for vaccine and control is greater than a specified value...
  49. ncbi Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis
    Marc Jeuland
    Department of Environmental Sciences and Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Value Health 12:899-908. 2009
    ..Our analysis incorporated new findings on vaccine herd protective effects...
  50. pmc Cholera vaccination in urban Haiti
    Vanessa Rouzier
    GHESKIO Centers, Port au Prince, Haiti Expanded Immunization Program, Ministry of Health and Population, Port au Prince, Haiti Division of Infectious Disease and International Health, Dartmouth Medical School, Hanover, New Hampshire Center for Global Health, Division of Infectious Disease, Weill Cornell Medical College, New York, New York
    Am J Trop Med Hyg 89:671-81. 2013
    ..The OCV intervention paved the way for the recent launching of a national cholera vaccination program integrated in a long-term ambitious and comprehensive plan to address Haiti's critical need in water security and sanitation...
  51. pmc Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in Bangladesh
    Firdausi Qadri
    International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka
    Infect Immun 73:6577-83. 2005
    ..cholerae O139. Consequently, this assay may be useful in studies of both O139-infected patients and recipients of O139 vaccines...
  52. ncbi Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults
    Rodrigo Valera
    Instituto Finlay, Centro de Investigacion, Desarrollo y Producción de Vacunas, P O Box 16017, La Lisa, Ciudad de la Habana 11600, Cuba
    Vaccine 27:6564-9. 2009
    ..All subjects in the vaccine group (24) seroconverted (100%). Results show that this vaccine is safe, well tolerated and immunogenic in healthy female and male volunteers...
  53. ncbi Experimental immunisation and protection of guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinase
    Duncan E S Stewart-Tull
    Division of Infection and Immunity, Institute of Biomedical and Life Sciences, Joseph Black Building, University of Glasgow, Glasgow G12 8QQ, UK
    Vaccine 22:2137-45. 2004
    ..cholerae cells and hence reduce delivery of toxin to receptors. These mucinases, neuraminidase and proteinases, may be useful components of acellular, toxoided cholera vaccines for human immunisation.
  54. ncbi Cost of immunization with a locally produced, oral cholera vaccine in Viet Nam
    A B Naficy
    Epidemiology Branch, National Institute of Child Health and Human Development, 6100 Executive Blvd, Suite 7B03, Rockville, MD 20852, USA
    Vaccine 19:3720-5. 2001
    ..91 per fully immunized person. Attempts to reduce the cost per dose of vaccine (e.g. the use of a monovalent vaccine against serogroup 01) are likely to have a large impact on the cost of future similar immunization campaigns...
  55. pmc Cost-effectiveness of oral cholera vaccine in a stable refugee population at risk for epidemic cholera and in a population with endemic cholera
    J Murray
    BASICS Basic Support for Institutionalizing Child Survival, Arlington, VA 22209, USA
    Bull World Health Organ 76:343-52. 1998
    ..cholera with high incidence and associated mortality among refugees have raised the question of whether oral cholera vaccines should be considered as an additional preventive measure in high-risk populations...
  56. ncbi New-generation vaccines against cholera
    John Clemens
    International Vaccine Institute, Seoul National University Research Park, San 4 8, Nakseongdae dong, Kwanak gu, Seoul 151 919, Korea
    Nat Rev Gastroenterol Hepatol 8:701-10. 2011
    ..Although early-generation parenteral cholera vaccines were abandoned as public health tools owing to their limited efficacy, newer-generation oral cholera vaccines ..
  57. doi What about cholera vaccines?
    Claire Lise Chaignat
    Expert Rev Vaccines 7:403-5. 2008
  58. ncbi Getting serious about cholera
    David A Sack
    International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh
    N Engl J Med 355:649-51. 2006
  59. pmc Novel type of specialized transduction for CTX phi or its satellite phage RS1 mediated by filamentous phage VGJ phi in Vibrio cholerae
    Javier Campos
    Departamento de Genetica, Centro Nacional de Investigaciones Cientificas, AP 6412, Havana, Cuba
    J Bacteriol 185:7231-40. 2003
    ..cholerae and the importance of our findings for the development of an environmentally safer live attenuated cholera vaccine...
  60. pmc Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility
    Anne L Bishop
    Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA 02111, USA
    Infect Immun 78:4402-20. 2010
    ..cholerae motility in vitro, with trends that parallel in vivo protection. Motility assays also reveal that a higher antibody titer is required to immobilize O139 compared to O1, a phenotype that is O139 capsule dependent...
  61. pmc Paperless registration during survey enumerations and large oral cholera mass vaccination in Zanzibar, the United Republic of Tanzania
    Mohammad Ali
    International Vaccine Institute, Kwanak PO Box 14, Seoul, 151 600, Republic of Korea
    Bull World Health Organ 88:556-9. 2010
    ..Field trials require extensive data preparation and complex logistics. The use of personal digital assistants (PDAs) can bypass many of the traditional steps that are necessary in a paper-based data entry system...
  62. ncbi Cholera in disasters: do vaccines prompt new hopes?
    Claire Lise Chaignat
    Global Task Force on Cholera Control, Department of Neglected Tropical Diseases, Communicable Diseases Cluster, World Health Organization, 20, Av Appia, 1211 Geneva 27, Switzerland
    Expert Rev Vaccines 7:431-5. 2008
    ..Fears of cholera outbreaks are often rife in such conditions and the pertinence of using cholera vaccines, now available on the market, merit attention...
  63. pmc Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine
    Daisuke Tokuhara
    Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108 8639, Japan
    Proc Natl Acad Sci U S A 107:8794-9. 2010
    ..cholerae and LT-ETEC challenges. Thus, MucoRice-CTB is an effective long-term cold chain-free oral vaccine that induces CTB-specific SIgA-mediated longstanding protection against V. cholerae- or LT-ETEC-induced diarrhea...
  64. doi Cholera: the need to translate research knowledge into effective preventive and control measures
    G Balakrish Nair
    Future Microbiol 3:379-81. 2008
  65. ncbi The true burden and risk of cholera: implications for prevention and control
    Jane N Zuckerman
    Academic Centre for Travel Medicine and Vaccines, WHO Collaborating Centre for Travel Medicine, Royal Free and University College Medical School, London, UK
    Lancet Infect Dis 7:521-30. 2007
    ..However, a vaccine against cholera is now available that has proven efficacy and tolerability in mass vaccination campaigns in low-income countries, and among travellers...
  66. ncbi Private demand for cholera vaccines in rural Matlab, Bangladesh
    Ziaul Islam
    Health Systems and Infectious Diseases Division, International Centre for Diarrhoeal Disease Research ICDDR, B, Dhaka, Bangladesh
    Health Policy 85:184-95. 2008
    To estimate household willingness to pay (WTP) for cholera vaccines in a rural area of Bangladesh, which had participated in a 1985 oral cholera vaccine trial.
  67. ncbi Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines
    Jean François Faucher
    Medical Research Unit, Albert Schweitzer Hospital, Lambarene, Gabon
    Clin Infect Dis 35:1147-54. 2002
    ..The A-P combination was highly effective for malaria prophylaxis, without interfering with the in vivo immunogenicity of CVD103-HgR and Ty21a vaccines, and it could therefore be simultaneously administered with these vaccines...
  68. ncbi Oral cholera vaccines: use in clinical practice
    David R Hill
    National Travel Health Network and Centre, London, UK
    Lancet Infect Dis 6:361-73. 2006
    Cholera continues to occur globally, particularly in sub-Saharan Africa and Asia. Oral cholera vaccines have been developed and have now been used for several years, primarily in traveller populations...
  69. ncbi Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial
    Suman Kanungo
    National Institute of Cholera and Enteric Diseases, Kolkata, India
    Vaccine 27:6887-93. 2009
    ..Responses to V. cholerae O139 were less pronounced but followed a similar pattern. We demonstrate that in a cholera-endemic area, the vaccine elicited vibriocidal responses after a single-dose of the vaccine...
  70. ncbi Effectiveness in prevention of travellers' diarrhoea by an oral cholera vaccine WC/rBS
    R Lopez-Gigosos
    International Vaccination Centre, Offices of the Health Area, Sub Delegation of the Government of Malaga, Paseo Marítimo de Pablo Ruiz Picasso 43, Malaga 29070, Spain
    Travel Med Infect Dis 5:380-4. 2007
    ..To investigate the effectiveness of an oral cholera vaccine (Dukoral((R))) in preventing travellers' diarrhoea...
  71. ncbi Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children
    H O Hallander
    Swedish Institute for Infectious Disease Control, Solna, Sweden
    Vaccine 21:138-45. 2002
    Serum responses to oral cholera vaccines were assessed in three paediatric vaccine trials, two in León, Nicaragua and one in Stockholm, Sweden...
  72. ncbi Can oral cholera vaccination play a role in controlling a cholera outbreak?
    Philippe Calain
    WHO Western Pacific Regional Office, Manila, Philippines
    Vaccine 22:2444-51. 2004
    ..9-84.6%) in the target population. Retrospective analysis suggests that mass vaccination with oral cholera vaccines can be a useful adjunct tool for controlling outbreaks, particularly if implemented early in association with ..
  73. ncbi Cholera vaccines
    E T Ryan
    Tropical and Geographic Medicine Center, Travelers Advice and Immunization Center, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA
    Clin Infect Dis 31:561-5. 2000
    ..cholerae for at least 6 months. No commercially available cholera vaccine protects against disease caused by V. cholerae serogroup O139. New cholera vaccines are being developed.
  74. pmc Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination
    C O Tacket
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Infect Immun 67:6341-5. 1999
    ..Peak stool V. cholerae excretion among placebo recipients was 1.1 x 10(7) CFU/g and among vaccinees was 4.9 x 10(2) CFU/g (P < 0.001). This vaccine could therefore be a safe and effective tool to prevent cholera in travelers...
  75. pmc Use of oral cholera vaccine in complex emergencies: what next? Summary report of an expert meeting and recommendations of WHO
    Claire Lise Chaignat
    Global Task Force on Cholera Control, World Health Organization, Avenue Appia 20, CH 1211 Geneva 27, Switzerland
    J Health Popul Nutr 25:244-61. 2007
    Two meetings of the World Health Organization (WHO)-in 1999 and 2002-had examined the potential use of oral cholera vaccines (OCVs) as an additional public-health tool for the control of cholera...
  76. ncbi Suppressive effect of zinc on antibody response to cholera toxin in children given the killed, B subunit-whole cell, oral cholera vaccine
    Firdausi Qadri
    International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh
    Vaccine 22:416-21. 2004
    ..Thus, zinc enhanced vibriocidal antibody response, but suppressed CT-antibody response, suggesting that zinc supplementation has different modulating effects on vibriocidal antibody response and CT-antibody response...
  77. ncbi [Examples for vaccines against diarrheal diseases--rotavirus and traveller's diarrhea]
    Herwig Kollaritsch
    Institut für Spezifische Prophylaxe und Tropenmedizin, Zentrum für Physiologie und Pathophysiologie, Medizinische Universität Wien, Kinderspitalgasse 15, Vienna, Austria
    Wien Med Wochenschr 157:102-6. 2007
    ..Both vaccines display 85-98% efficacy against severe rotavirus disease and an excellent tolerability with no difference in side reactions to the placebo controls, particularly with respect to intussusceptions...
  78. ncbi Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants
    Firdausi Qadri
    ICDDR, B Centre for Health and Population Research, Bangladesh
    Vaccine 25:231-8. 2007
    ..The responses to the reduced dose was lower. These studies demonstrate that Peru-15 at a dose of 2x10(8)cfu is safe and immunogenic in children in Bangladesh...
  79. pmc CTXphi immunity: application in the development of cholera vaccines
    H H Kimsey
    Division of Geographic Medicine and Infectious Diseases, Tupper Research Institute, Tufts New England Medical Center 041, 750 Washington Street, Boston, MA 02111, USA
    Proc Natl Acad Sci U S A 95:7035-9. 1998
    ..cholerae vaccine strains effectively protected these vaccines from CTXphi infection. Introduction of rstR into V. cholerae vaccine strains should enhance their biosafety...
  80. pmc A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali
    R T Perry
    Department of Pediatrics, University of Maryland School of Medicine, Baltimore, USA
    Bull World Health Organ 76:63-71. 1998
    ..These results encourage further evaluations of this single-dose, oral cholera vaccine in high-risk populations such as refugees in sub-Saharan Africa...
  81. ncbi Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR
    Jean Francois Viret
    Berna Biotech Ltd, Rehhagstrasse 79, CH 3018 Berne, Switzerland
    Vaccine 22:2457-69. 2004
    ..In this contribution we address selected aspects of the risk assessment of live attenuated bacterial vaccines covered in the course of the registration of vaccine strain CVD 103-HgR as a recombinant live oral vaccine against cholera...
  82. pmc Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam
    D D Trach
    National Institute of Hygiene and Epidemiology, Hanoi, Viet Nam
    Bull World Health Organ 80:2-8. 2002
    ..To evaluate a killed oral cholera vaccine produced in Viet Nam, and to compare the Vietnamese vaccine with one that is licensed internationally...
  83. ncbi The value of cholera vaccines reassessed
    Roger I Glass
    Viral Gastroenteritis Section, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Lancet 366:7-9. 2005
  84. ncbi Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh
    Firdausi Qadri
    International Centre for Diarrhoeal Disease Research, Bangladesh ICDDR, B Centre for Health and Population Research, Dhaka, Bangladesh
    J Infect Dis 192:573-9. 2005
    ..A lower immunological response against cholera toxin B subunit was detected.CONCLUSIONS. The safety and immunogenicity of this Peru-15 vaccine candidate indicates the usefulness of future studies in Bangladesh, where cholera is endemic...
  85. ncbi Vaccines on trial
    Paroma Basu
    Nature 436:484. 2005
  86. pmc The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers
    Luis Garcia
    Centro Nacional de Investigaciones Cientificas, P O Box 6412, Avenida 25, Esquina a 158, Ciudad de La Habana, Cuba
    Infect Immun 73:3018-24. 2005
    ..cholerae 3008. We recommend that additional vaccine lots of 638 be prepared under good manufacturing practices for further evaluation...
  87. ncbi Cholera vaccines for the developing world
    Anna Lena Lopez
    International Vaccine Institute, Seoul, Korea
    Hum Vaccin 4:165-9. 2008
    ..Since 1999, the World Health Organization has advocated the use of oral cholera vaccines as an adjunct in the control of cholera...
  88. pmc Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice
    J Y Wu
    Department of Microbiology and Immunology, Dartmouth Medical School, Hanover, New Hampshire 03755, USA
    Infect Immun 69:7695-702. 2001
    ..These results indicate that specific regions of TcpA, including those delineated by the peptides used in this study, have the potential to be incorporated into an effective defined subunit vaccine for cholera...
  89. ncbi Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrhea
    Jonas Lundkvist
    i3innovus, Stockholm, Sweden
    J Travel Med 16:28-34. 2009
    ....
  90. ncbi Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea
    Robert Steffen
    Institute for Social and Preventive Medicine ISPM, World Health Organization WHO Collaborating Center for Travelers Health, University of Zurich, Switzerland
    J Travel Med 12:102-7. 2005
  91. ncbi Cholera vaccines
    Shahjahan Kabir
    Lancet Infect Dis 7:176-8; author reply 178. 2007
  92. pmc Exploiting cholera vaccines as a versatile antigen delivery platform
    Anisia J Silva
    Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Dr, SW Atlanta, GA 30310, USA
    Biotechnol Lett 30:571-9. 2008
    ..Foreign antigens can be delivered to the immune system with cholera vaccines by expressing heterologous antigens in live attenuated vectors, as fusion proteins with cholera toxin ..
  93. ncbi A Vibrio cholerae serogroup O1 vaccine candidate against CTX ET Phi infection
    Meiying Yan
    State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, PR China
    Vaccine 25:4046-55. 2007
    ..Thus, IEM109 is a stable vaccine candidate that evokes not only antitoxic and vibriocidal immunities, but also resistance to the El Tor biotype CTX Phi infection...
  94. ncbi A semi-automated vibriocidal assay for improved measurement of cholera vaccine-induced immune responses
    Jae Seung Yang
    Laboratory Sciences Division, International Vaccine Institute, Seoul 151 600, Republic of Korea
    J Microbiol Methods 71:141-6. 2007
    ....
  95. ncbi [Cholera: recent acquisitions]
    Salvatore Nardiello
    Dipartimento Assistenziale di Malattie Infettive, Seconda Universita degli Studi di Napoli
    Infez Med 15:85-92. 2007
    ..We have reviewed the most recent hypothesis on the ecology of cholera, in particular on the origin of epidemics. Recent developments in the fields of therapy and prophylaxis of cholera are also reported...
  96. ncbi [Selection of attenuated Vibrio cholerae strains to obtain oral attenuated candidate vaccines against cholera]
    Hilda María García
    Instituto Finlay, Ciudad de La Habana, Cuba
    Rev Cubana Med Trop 57:92-104. 2005
    ..All the strains were sensitive to tetracycline and doxoclycine. They showed their attenuation and immunogenicity in animal models. The strains 638 and 1333 proved to be immunogenic and non reactogenic in volunteers...
  97. ncbi Response to "questionable merits of the field trial of an oral killed whole cell cholera vaccine in Vietnam during 1998-2003" Vaccine 2007;25(8):1353-4
    Vu Dinh Thiem
    Vaccine 25:7981-3. 2007
  98. ncbi Progress towards development of a cholera subunit vaccine
    Ronald K Taylor
    Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, NH 03756, USA
    Chem Biodivers 1:1036-57. 2004
    ..cholerae exposed or vaccinated individuals. This review discusses the current cholera vaccines and compares the advantages of a cholera subunit vaccine to that of the whole cell vaccines...
  99. ncbi Induction of protective immunity by synthetic Vibrio cholerae hexasaccharide derived from V. cholerae O1 Ogawa lipopolysaccharide bound to a protein carrier
    Anatoly Chernyak
    Laboratory of Medicinal Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 185:950-62. 2002
    ..Further studies are required to increase understanding of the reason for differential protection...
  100. ncbi Infection and immunity to Vibrio cholerae, Salmonella typhimurium and Escherichia coli in a rabbit model
    P A Guinee
    National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands
    Zentralbl Bakteriol Mikrobiol Hyg A 270:260-9. 1988
    ..Therefore, further attenuation of non-toxigenic V. cholerae strains by means of stable deletions in nutritional genes seems to be the most promising way to obtain acceptable vaccine candidates...

Research Grants31

  1. Protecutive immunity to human cholera in Bangladesh
    Edward T Ryan; Fiscal Year: 2013
    ..Unfortunately, protective immunity following cholera is not currently understood, and available cholera vaccines either fail to produce full protective efficacy or induce less than optimal and relatively short-lived immune ..
  2. Epidemiology and Ecology of Vibrio cholerae in Bangladesh
    Richard Bradley Sack; Fiscal Year: 2013
    ..The very recent availability of inexpensive oral cholera vaccines makes this objective even more relevant...
  3. V. cholerae proteins are required for biofilm growth-vaccine targets
    HAVVA FITNAT YILDIZ; Fiscal Year: 2011
    ..studies are important to determine if biofilm antigens are relevant targets for the immune system and thus cholera vaccines. The proposed study brings together the expertise of two scientists, Drs...
  4. Development of a live, genetically-attenuated cholera vaccine prototype that coul
    JORGE ANTONIO BENITEZ; Fiscal Year: 2013
    ..and Haiti, have strengthened a recommendation by the World Health Organization for the preventive use of oral cholera vaccines to avert outbreaks and control their spread...
  5. High-throughput proteomic study of protective immunity in human cholera infection
    Richelle C Charles; Fiscal Year: 2013
    ..Although cholera vaccines do induce a protective immune response, immunity is short-lived, lasting approximately 6-24 months...
  6. High throughput NAPPA-proteoimmunomics and Vibrio cholerae vaccine development
    Edward T Ryan; Fiscal Year: 2012
    ..The mediators of protective immunity against cholera are poorly understood, and although a number of cholera vaccines have been developed, each has significant limitations...
  7. A novel cholera subunit vaccine based on 4 colonization factors
    WILLIAM FRANKLIN WADE; Fiscal Year: 2010
    ..The killed W-C cholera vaccines do not express immunogenic levels of several Vc protective antigens that are expressed during infection...
  8. O-Specific Polysaccharide Responses and Cholera
    Edward T Ryan; Fiscal Year: 2013
    ..cholerae LPS, but that recipients of currently available oral killed cholera vaccines do not...
  9. DEVELOPMENT OF A LIVE ORAL CHOLERA VACCINE
    James B Kaper; Fiscal Year: 2010
    ..We have also generated new insights into intestinal inflammation caused by these reactogenic cholera vaccines by using gene arrays of epithelial cell transcriptional responses...
  10. Causal inference in infectious disease prevention studies
    Michael G Hudgens; Fiscal Year: 2013
    ..A motivating data set is from a trial of cholera vaccines in Bangladesh...
  11. Cholera Pathogenesis, mucinase activity and motility
    Jorge Benitez; Fiscal Year: 2007
    ..cholerae main virulence factors: cholera toxin and toxin co-regulated in the infant mouse intestine. This knowledge will facilitate the development of improved cholera vaccines.
  12. Immune responses to Vibrio cholerae in children
    DANIEL TED LEUNG; Fiscal Year: 2013
    ..Despite this, currently available cholera vaccines achieve a lower efficacy and a shorter duration of protection in young children compared to that achieved in ..
  13. T-cell immune responses to Vibrio cholerae infection
    Jason B Harris; Fiscal Year: 2011
    ..An improved understanding of T-cell responses to natural cholera and vaccination may lead directly to improvements in cholera vaccines.
  14. Immune Responses to Vibrio cholerae infection and vaccination in Haiti
    LOUISE CATHERINE IVERS; Fiscal Year: 2013
    ..Remarkably little is known about immune responses to cholera and oral cholera vaccines in immunologically na[unreadable]ve populations, and in populations outside of historically cholera endemic ..
  15. ANALYSIS OF V CHOLERAE GENES INVOLVED IN COLONIZATION
    KENNETH PETERSON; Fiscal Year: 1993
    ..Knowledge gained from the proposed investigation may provide a basis for the development of efficacious cholera vaccines.
  16. Mucosal immune response to oral cholera vaccine Peru 15
    Firdausi Qadri; Fiscal Year: 2007
    ..cholerae. ..
  17. BACTERIAL LIVE VECTOR-BASED VACCINE AGAINST MALARIA
    Myron Levine; Fiscal Year: 2004
    ..falciparum, and by these effects working in concert, we will ultimately be able to prevent disease completely in some subjects and to markedly ameliorate disease severity in others. ..
  18. RECOMBINANT & LIVE ORAL SALMONELLA TYPHI HYBRID VACCINES
    Myron Levine; Fiscal Year: 2008
    ..abstract_text> ..
  19. High throughput proteomic analysis of Salmonella enterica
    Edward Ryan; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  20. Mucosal Immunity to Antigens Expressed by V.cholerae
    Edward Ryan; Fiscal Year: 2006
    ..difficile toxin A is injected into ligated ileal loops of vaccinated and control animals. ..
  21. Application of IVIAT to Bacillus anthracis
    Edward Ryan; Fiscal Year: 2004
    ..IVIAT is an established protocol in our laboratory, and this preliminary collaborative study should lay a foundation for subsequent analysis of identified B. anthracis genes and their products. ..
  22. Transcutaneous and oral-transcutaneous cholera immunization with TcpA and Peru15
    Edward Ryan; Fiscal Year: 2008
    ..Protective immunity to V. cholerae is poorly understood, and development of highly effective cholera vaccines has been problematic...
  23. VIBRIO CHOLERAE TCP AND LPS SUBUNIT VACCINE, EPITOPES AN
    William Wade; Fiscal Year: 2004
    ..cholerae colonization factor and a protective antigen. Together, the expertise of these two research groups will provide a unique opportunity to develop and evaluate V: cholerae subunit vaccines using new approaches. ..
  24. Live Attenuated Bacterial Vaccines Against Anthrax
    SIMS KOCHI; Fiscal Year: 2002
    ..The successful accomplishment of these aims will provide new anthrax vaccines with the potential to confer protective immunity by oral immunization in humans. ..
  25. Dispersin from Enteroaggregative E. coli
    James Nataro; Fiscal Year: 2004
    ..Each protein will be localized and their roles addressed using mutagenesis and biochemical strategies. ..
  26. Protective anti-LPS antibodies: what are they?
    William Wade; Fiscal Year: 2006
    ..We will clarify the "type" of anti-V. cholerae LPS antibodies that are protective and thus substantiate or not the use of Inaba neoconjugates as a vaccine component. ..
  27. Development and cGMP Manufacture of a Vitrified Typhoid Vaccine
    SIMS KOCHI; Fiscal Year: 2006
    ..Meeting these goals will facilitate the advance of Ty800 as an oral, single-dose vaccine that can be delivered outside of the storage cold chain. [unreadable] [unreadable]..
  28. Live Vector Vaccines Against Agents of Bioterror
    James Nataro; Fiscal Year: 2007
    ..During the term of the award, we will generate a series of vaccine candidates for immediate Phase 1 human trials. ..
  29. AUTOTRANSPORTERS OF ENTEROBACTERIACEAE
    James Nataro; Fiscal Year: 2008
    ..This work will extend knowledge on a very common set of virulence factors and elicidate important features of the most common means of outer membrane translocation in gram negative bacteria. ..
  30. Statistical Methods in HIV Vaccine Efficacy Trials
    Peter Gilbert; Fiscal Year: 2009
    ..By improving the design and analysis of efficacy and NHP trials for addressing these areas, the project will benefit public health. ..